Holen Sie sich die Stockscreener-App
39.80
2.81%
-1.15
Handel nachbörslich:
39.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$40.95
Offen:
$40.31
24-Stunden-Volumen:
418.81K
Relative Volume:
0.60
Marktkapitalisierung:
$1.49B
Einnahmen:
$272.30M
Nettoeinkommen (Verlust:
$-5.14M
KGV:
-243.43
EPS:
-0.1635
Netto-Cashflow:
$42.76M
1W Leistung:
+0.82%
1M Leistung:
+3.51%
6M Leistung:
-24.59%
1J Leistung:
+1.74%
1-Tages-Spanne:
$38.80
$40.38
1-Wochen-Bereich:
$38.21
$42.71
52-Wochen-Spanne:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
39.80 | 1.58B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
18.24 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.16 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.93 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.17 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
512.88 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | BTIG Research | Buy |
| 2025-06-10 | Eingeleitet | William Blair | Outperform |
| 2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-04 | Bestätigt | B. Riley Securities | Buy |
| 2024-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-09-24 | Eingeleitet | Aegis Capital | Buy |
| 2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth - Sahm
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Releases Q2 2026 Financial Results - AlphaStreet
Harrow Q2 Earnings Call Highlights - MarketBeat
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
Harrow Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Harrow, Inc. (HROW) Stock Analysis: A 66% Potential Upside Awaits Investors in the Eyecare Pharmaceutical Space - DirectorsTalk Interviews
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline - TradingView
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story - simplywall.st
HROW Looks 8.5% Undervalued on GF Value™ - GuruFocus
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Harrow affirms FY26 sales guidance of $350-365M vs $348.468M est - scanx.trade
HROW Looks 8.5% Undervalued on GF Value™ Amid Mixed Growth Signa - GuruFocus
Harrow, Inc. Announces $17.3 Million Net Loss in Q2 2026 Amid Revenue Growth - Kalkine Media
Harrow: Q2 Earnings Snapshot - marketscreener.com
Is Harrow Inc (HROW) Positioned for Growth After Q2 Earnings Rep - GuruFocus
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harrow Inc-Aktie (HROW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Option Exercise |
35.96 |
11,250 |
404,550 |
11,250 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Sale |
40.00 |
11,250 |
450,000 |
0 |
| Graves Adrienne L | Director |
May 18 '26 |
Buy |
31.07 |
1,000 |
31,070 |
1,000 |
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
1.12%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):